Graft versus-host disease
Conditions
Interventions
Oral cGVHD:NA
Non-oral cGVHD:NA
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. From December 2024 to December 2026, 18-50 years old patients diagnosed with oral chronic GVHD after allogeneic hematopoietic stem cell transplantation in our center were enrolled as the experimental group, and non-oral chronic GVHD patients after allogeneic hematopoietic stem cell transplantation were enrolled as the control group. 2. Voluntarily participate in this study, and sign the informed consent; 3. without serious damage of vital organs: (1) creatinine =2g/dl; (3) Cardiac ejection index >50%; (4) heme >9g/dL, bilirubin < 2.0mg/dl; 4. Blood routine, liver and kidney function, coagulation routine were normal; 5. No other contraindications to salivary gland biopsy.
Exclusion criteria
Exclusion criteria: 1. There is active bleeding caused by drugs or thrombocytopenia, and clinically uncontrolled active infection; 2. Pregnant or lactating women; 3. Severe heart, kidney or liver dysfunction; 4. Drug-related or other mucosal diseases and oral diseases, diabetes; 5. Inability to understand or follow the study protocol due to clinical symptoms of brain dysfunction or severe mental disease; 6. Patients with severe acute allergic reactions; 7. The investigators considered that other reasons were not appropriate for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Salivary glands 10× Genomics Visium space transcriptome specifically expressed genes;Salivary cytokines;Exfoliative cellular components of the oral mucosa; | — |
Countries
China
Contacts
Public ContactXi Zhang
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed